Fuechtenbusch M, et al. - Authors assessed weight loss in patients with type 2 diabetes (T2D) mellitus receiving once-weekly dulaglutide plus insulin lispro vs daily insulin glargine plus insulin lispro. They observed the following differences/targets were more pronounced with dulaglutide 1.5 mg than with insulin glargine: LSM weight change difference: -3.23 kg; proportions of individuals without any weight gain: 49.0% vs 19.0%; with weight loss ≥3%: 21.7% vs 5.7%; ≥5%: 10.5% vs 2.4%; HbA1c <7% without weight gain: 26.2% vs 7.9%; HbA1c <7% and ≥3% weight loss: 11.9% vs 1.4%, respectively. They noticed no significant alterations in treatment outcomes for these parameters across BMI categories.